Detalhe da pesquisa
1.
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Nat Cancer
; 4(9): 1345-1361, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743366
2.
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Mol Cancer Res
; 20(5): 722-734, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149545
3.
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.
Cancer Res
; 82(6): 1110-1127, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074756
4.
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
NPJ Precis Oncol
; 6(1): 88, 2022 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418460
5.
Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance.
JCO Precis Oncol
; 6: e2200048, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35952322
6.
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Cancer Discov
; 12(5): 1233-1247, 2022 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135829
7.
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling.
Dis Model Mech
; 15(1)2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34841430
8.
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
J Thorac Oncol
; 16(7): 1149-1165, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839363
9.
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
Clin Cancer Res
; 27(11): 3154-3166, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824166
10.
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
Clin Cancer Res
; 27(4): 1184-1194, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33229458
11.
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Commun Biol
; 3(1): 776, 2020 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33328556
12.
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Dis Model Mech
; 2020 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33318047
13.
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Nat Cancer
; 4(10): 1526, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814012
14.
Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
Clin Lung Cancer
; 21(1): e25-e29, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31690489